Fasciola hepatica tegumental antigens indirectly induce an M2 macrophage-like phenotype in vivo

Parasite Immunology

Volumn 36, Issue 10, 2014, Pages 531-539

  Adams, P N ^a   Aldridge, A ^a   Vukman, K V ^a   Donnelly, S ^b   Oneill, Sandra M ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Dendritic cells; Eosinophils; Fasciola hepatica; Il 13; M2 macrophages; STAT6

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PARASITE ANTIGEN; STAT6 PROTEIN; STAT6 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FASCIOLA HEPATICA; FASCIOLIASIS; GENE EXPRESSION; IMMUNE RESPONSE; INTEGUMENT; M2 MACROPHAGE; MACROPHAGE; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEAL EXUDATE CELL; PERITONEUM MACROPHAGE; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DENDRITIC CELL; IMMUNOLOGY; MAST CELL; METABOLISM; PARASITOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, HELMINTH; DENDRITIC CELLS; FASCIOLA HEPATICA; FASCIOLIASIS; INTERLEUKIN-13; MACROPHAGES; MACROPHAGES, PERITONEAL; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; STAT6 TRANSCRIPTION FACTOR;

EID: 84908288900     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12127     Document Type: Article

References (32)

1. Mas-Coma S. Epidemiology of fascioliasis in human endemic areas. J Helminthol 2005; 79: 207-216.
2. Dalton JP, Robinson MW, Mulcahy G, ONeill SM & Donnelly S. Immunomodulatory molecules of Fasciola hepatica: candidates for both vaccine and immunotherapeutic development. Vet Parasitol 2013; 195: 272-285.
3. Mulcahy G, OConnor F, Clery D, et al. Immune responses of cattle to experimental anti-Fasciola hepatica vaccines. Res Vet Sci 1999; 67: 27-33.
4. ONeill SM, Brady MT, Callanan JJ, et al. Fasciola hepatica infection downregulates Th1 responses in mice. Parasite Immunol 2000; 22: 147-155.
5. Donnelly S, Stack CM, ONeill SM, Sayed AA, Williams DL & Dalton JP. Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechanism involving alternatively activated macrophages. FASEB J 2008; 22: 4022-4032.
6. Hamilton CM, Dowling DJ, Loscher CE, Morphew RM, Brophy PM & ONeill SM. The Fasciola hepatica tegumental antigen suppresses dendritic cell maturation and function. Infect Immun 2009; 77: 2488-2498.
7. Vukman KV, Adams PN, Metz M, Maurer M & ONeill SM. Fasciola hepatica tegumental coat impairs mast cells ability to drive Th1 immune responses. J Immunol 2013; 190: 2873-2879.
8. Vukman KV, Adams PN & ONeill SM. Fasciola hepatica tegumental coat antigen suppresses MAPK signalling in dendritic cells and up-regulates the expression of SOCS3. Parasite Immunol 2013; 35: 234-238.
9. Vukman KV, Adams PN, Dowling D, Metz M, Maurer M & ONeill SM. The effects of Fasciola hepatica tegumental antigens on mast cell function. Int J Parasitol 2013; 43: 531-9.
10. Donnelly S, ONeill SM, Sekiya M, Mulcahy G & Dalton JP. Thioredoxin peroxidase secreted by Fasciola hepatica induces the alternative activation of macrophages. Infect Immun 2005; 73: 166-173.
11. Guasconi L, Serradell MC, Garro AP, Iacobelli L & Masih DT. C-type lectins on macrophages participate in the immunomodulatory response to Fasciola hepatica products. Immunology 2011 Jul; 133: 386-396.
12. Gordon S & Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604.
13. Loke P, Gallagher I, Nair MG, et al. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol 2007; 179: 3926-3936.
14. Chen F, Liu Z, Wu W, et al. An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. Nat Med 2012; 18: 260-266.
15. Savage J, Meaney M, Brennan GP, Hoey E, Trudgett A & Fairweather I. Increased action of triclabendazole (TCBZ) in vitro against a TCBZ-resistant isolate of Fasciola hepatica following its co-incubation with the P-glycoprotein inhibitor, R(+)-verapamil. Exp Parasitol 2013; 135: 642-653.
16. Haçariz O, Sayers G, Flynn RJ, Lejeune A & Mulcahy G. IL-10 and TGF-beta1 are associated with variations in fluke burdens following experimental fasciolosis in sheep. Parasite Immunol 2009; 31: 613-622.
17. Donnelly S, ONeill SM, Stack CM, et al. Helminth cysteine proteases inhibit TRIFdependent activation of macrophages via degradation of TLR3. J Biol Chem 2010; 285: 3383-3392.
18. Dowling DJ, Hamilton CM, Donnelly S, et al. Major secretory antigens of the helminth Fasciola hepatica activate a suppressive dendritic cell phenotype that attenuates Th17 cells but fails to activate Th2 immune responses. Infect Immun 2010; 78: 793-801.
19. Van Dyken SJ & Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol 2013; 31: 317-343.
20. Liang HE, Reinhardt RL, Bando JK, Sullivan BM, Ho IC & Locksley RM. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol 2011; 13: 58-66.
21. Pope SM, Brandt EB, Mishra A, et al. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 2001; 108: 594-601.
22. Lam KP, Chu YT, Lee MS, et al. Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells. Pediatr Allergy Immunol 2011; 22: 431-439.
23. Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med 2003; 197: 687-701.
24. Mikita T, Campbell D, Wu P, Williamson K & Schindler U. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell Biol 1996; 16: 5811-5820.
25. Kaplan MH, Schindler U, Smiley ST & Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 313-319.
26. Kaplan MH, Whitfield JR, Boros DL & Grusby MJ. Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. J Immunol 1998; 160: 1850- 1856.
27. Kuperman D, Schofield B, Wills-Karp M & Grusby MJ. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 1998; 187: 939-948.
28. Herbert DR, Yang JQ, Hogan SP, et al. Intestinal epithelial cell secretion of RELMbeta protects against gastrointestinal worm infection. J Exp Med 2009; 206: 2947-2957.
29. Nair MG, Du Y, Perrigoue JG, et al. Alternatively activated macrophage-derived RELM-{alpha} is a negative regulator of type 2 inflammation in the lung. J Exp Med 2009; 206: 937-952.
30. Pesce JT, Ramalingam TR, Wilson MS, et al. Retnla (relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog 2009; 5: e1000393.
31. Ramalingam TR, Pesce JT, Sheikh F, et al. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin receptor alpha1 chain. Nat Immunol 2008; 9: 25-33.
32. Barron L & Wynn TA. Macrophage activation governs schistosomiasis-induced inflammation and fibrosis. Eur J Immunol 2011; 41: 2509-2514.